These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3514515)

  • 21. [Studies on the bioavailability of beta-aescin following oral administration of various dosage forms. Commentary on the work of Kunz et al. as well as Schrader et al., published in this journal].
    Dittgen M; Zimmermann H; Wober W; Höflich C; Breitbarth H; Timpe C
    Pharmazie; 1996 Aug; 51(8):608-10. PubMed ID: 8975254
    [No Abstract]   [Full Text] [Related]  

  • 22. [Site-specific drug delivery systems II. Buccal delivery systems].
    Szente V; Zelkó R
    Acta Pharm Hung; 2007; 77(4):217-22. PubMed ID: 18290541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Possibilities and problems of organ-selective active principles and drugs].
    Hamacher H
    Pharmazie; 1981 Jun; 36(6):391-9. PubMed ID: 7025022
    [No Abstract]   [Full Text] [Related]  

  • 24. [Biological availability of two theophylline preparations (author's transl)].
    Kaik G
    Prax Klin Pneumol; 1982 Jun; 36(6):294-6. PubMed ID: 7111181
    [No Abstract]   [Full Text] [Related]  

  • 25. Bioavailability of controlled-release metoclopramide. 1st communication: single dose study.
    Beckett AH; Behrendt WA; Hadzija BW
    Arzneimittelforschung; 1987 Feb; 37(2):221-4. PubMed ID: 3580026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. For peptide drugs like insulin: new protective coat for oral administration.
    Am Pharm; 1986 Nov; NS26(11):15-6. PubMed ID: 3541559
    [No Abstract]   [Full Text] [Related]  

  • 27. [Gastroretentive dosage forms].
    Kiss D; Zelkó R
    Acta Pharm Hung; 2005; 75(3):169-76. PubMed ID: 16318241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selection of drug candidates for gastroretentive dosage forms: pharmacokinetics following continuous intragastric mode of administration in a rat model.
    Kagan L; Hoffman A
    Eur J Pharm Biopharm; 2008 May; 69(1):238-46. PubMed ID: 18068342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of an immediate release, a controlled release and a two pulse dosage form in dogs.
    Löbenberg R; Kim JS; Amidon GL
    Eur J Pharm Biopharm; 2005 May; 60(1):17-23. PubMed ID: 15848051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioavailability of controlled-release metoclopramide. 2nd communication: multiple dose study.
    Beckett AH; Behrendt WA; Hadzija BW
    Arzneimittelforschung; 1987 Feb; 37(2):224-8. PubMed ID: 3580027
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained delivery of intact drug to the colon: mesalamine formulation and temporal gastrointestinal transit analysis.
    Chuong MC; Christensen JM; Ayres JW
    Pharm Dev Technol; 2009; 14(1):116-25. PubMed ID: 18821272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Insulin: from 40 to 100 units per milliliter].
    Heine RJ
    Ned Tijdschr Geneeskd; 1989 Dec; 133(49):2462-3. PubMed ID: 2687706
    [No Abstract]   [Full Text] [Related]  

  • 33. [Study of bioavailability parameters of propranolol in cirrhotic patients after oral administration of the delayed-action form].
    Blanc M; Cales P; Grasset D; Ravaud A; Meskens C; Cotonat J; Pascal JP
    Therapie; 1987; 42(2):187-91. PubMed ID: 3616995
    [No Abstract]   [Full Text] [Related]  

  • 34. [Pharmacokinetics and relative bioavailability of a new oral sustained-release form of mexiletine in healthy subjects].
    Santoni Y; Bruno R; Fornaris M; Egre A; Danays T; Cano JP
    Therapie; 1983; 38(4):341-4. PubMed ID: 6648880
    [No Abstract]   [Full Text] [Related]  

  • 35. [Situational administration of analgesics. Modern dosage forms for opioids].
    Bartholomäus J
    Pharm Unserer Zeit; 2002; 31(1):74-81. PubMed ID: 11852660
    [No Abstract]   [Full Text] [Related]  

  • 36. [Utilization of analog computers in the development of dosage forms].
    Frömming KH; Lippold B; Garrett ER
    Mitt Dtsch Pharm Ges Pharm Ges DDR; 1971 Sep; 41(9):205-47. PubMed ID: 4939073
    [No Abstract]   [Full Text] [Related]  

  • 37. [Some factors influencing the bioavailability of zinc in oral pharmaceutical dosage forms].
    Neve J; Hanocq M; Peretz A; Abi Khalil F; Pelen F
    J Pharm Belg; 1993; 48(1):5-11. PubMed ID: 8483101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How many oral iron preparations does a prescriber need?
    Drug Ther Bull; 1979 Apr; 17(9):33-4. PubMed ID: 446268
    [No Abstract]   [Full Text] [Related]  

  • 39. Workshop II report: scaleup of oral extended release dosage forms.
    Skelly JP; Van Buskirk GA; Arbit HM; Amidon GL; Augsburger L; Barr WH; Berge S; Clevenger J; Dighe S; Fawzi M
    J Pharm Sci Technol; 1994; 48(2):95-101. PubMed ID: 8032802
    [No Abstract]   [Full Text] [Related]  

  • 40. [Comparison of bioavailability and pharmacokinetic profiles between Theodur and a new sustained-release theophylline formulation].
    Morishita M; Nagai T; Ishizaki T; Suganuma T; Kushida K; Minegishi A
    Arerugi; 1986 Nov; 35(11):1099-104. PubMed ID: 3827603
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.